-
公开(公告)号：US20200289509A1
公开(公告)日：2020-09-17
申请号：US16765778
申请日：2017-11-16
发明人： Julien LEFRANC , Norbert SCHMEES , Ulrike RÖHN , Ludwig ZORN , Judith GÜNTHER , Ilona GUTCHER , Lars RÖSE , Benjamin BADER , Detlef STÖCKIGT , Michael PLATTEN
IPC分类号： A61K31/506 , C07D403/04 , C07D401/04 , C07D409/04 , C07D413/04 , C07D401/14 , C07D409/14 , C07D405/14
摘要： The present invention covers 2-hetarylpyrimidine-4-carboxamide compounds of general formula (I): in which X, Y, Z, R1, R2 and R4 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.
-
公开(公告)号：US12054458B2
公开(公告)日：2024-08-06
申请号：US18186043
申请日：2023-03-17
发明人： Jens Cardinale , Martin Schaefer , Klaus Kopka , Matthias Eder , Ulrike Bauder-Wuest , Michael Eisenhut , Martina Benesova , Uwe Haberkorn , Frederik L. Giesel
IPC分类号： C07D213/61 , A61K38/00 , A61K51/04 , A61P35/00 , C07B59/00 , C07K7/02 , G01N33/574
CPC分类号： C07D213/61 , A61K51/04 , A61K51/0455 , A61P35/00 , C07B59/002 , C07K7/02 , G01N33/57434 , A61K38/00 , C07B2200/05
摘要： The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers and imaging agents for various disease states of prostate cancer.
-
公开(公告)号：US20240240190A1
公开(公告)日：2024-07-18
申请号：US18562167
申请日：2022-05-20
IPC分类号： C12N15/113 , A61P35/00 , G01N33/50
CPC分类号： C12N15/1138 , A61P35/00 , G01N33/5026 , C12N2310/14 , G01N2500/10
摘要： The present invention relates to an inhibitor of mitoferrin-2 for use in treating a cancer with reduced activity of mitoferrin-1 in a subject. The present invention also relates to a method for identifying an inhibitor of mitoferrin-2 comprising (a) contacting a (i) host cell with a reduced mitoferrin-1 activity and (ii) a host cell with a non-reduced mitoferrin-1 activity with a candidate inhibitor of mitoferrin-2. (b) determining growth and/or morphology of the host cells of step (a): (c) identifying an inhibitor of mitoferrin-2 if a growth arrest and/or abnormal morphology is/are detected in step (b) in the host cell having the reduced activity of mitoferrin-1 but not in the host cell with the non-reduced activity of mitoferrin-1. The present invention further relates to a method for identifying a subject susceptible to cancer treatment by an inhibitor of mitoferrin-2, comprising (A) determining mitoferrin-1 activity in a sample of said subject, preferably a sample of cancer cells, and (B) identifying a patient susceptible to cancer treatment by an inhibitor of mitoferrin-2 based on determining step (A).
-
公开(公告)号：US20240197909A1
公开(公告)日：2024-06-20
申请号：US17998318
申请日：2021-05-12
申请人： LIFE SCIENCE INKUBATOR GMBH & Co. KG , DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS
发明人： Armin KÜBELBECK , Angelika RIEMER , Sebastian KRUSE , Eva FEIDT , Agnieszka GRABOWSKA , Ellen JUNGLAS
CPC分类号： A61K47/6931 , A61K39/39 , A61K2039/55555 , A61K2039/55561
摘要： The disclosure relates to immunological compositions (immunostimulants) based on nanoparticles as carrier for adjuvants, optionally in combination with antigens or epitopes, in particular for the use of the compositions for immunoprophylaxis or immunotherapy.
-
公开(公告)号：US11931349B2
公开(公告)日：2024-03-19
申请号：US16766408
申请日：2018-11-23
IPC分类号： A61K31/4418 , A61K31/16 , A61K31/345 , A61K31/4196 , A61K31/44 , A61K31/4412 , A61K31/444 , A61K45/06 , A61P35/00
CPC分类号： A61K31/4418 , A61K31/16 , A61K31/345 , A61K31/4196 , A61K31/44 , A61K31/4412 , A61K31/444 , A61K45/06 , A61P35/00
摘要： The present invention relates to a pharmaceutically compatible iron chelator or a prodrug thereof for use in treating and/or preventing cancer in a subject suspected or known to comprise hypoxic cancer cells, and use in treatment and/or prevention of a human papillomavirus (HPV) related lesion. The present invention further relates to a use of an iron chelator or prodrug thereof for inducing senescence in a cancer cell, preferably a hypoxic cancer cell; and to a method for inducing an irreversible proliferation arrest in cancer cells comprising a) contacting said cancer cells with an iron chelator or prodrug thereof and, thereby, b) inducing an irreversible proliferation arrest in said cancer cells.
-
公开(公告)号：US11899089B2
公开(公告)日：2024-02-13
申请号：US15733413
申请日：2019-01-24
CPC分类号： G01R33/58 , A61B5/0042 , A61B5/055 , A61B5/4064 , G01R33/4804 , G01R33/56341 , G09B23/286
摘要： A phantom calibration body (110) for a method for determining at least one quantitative diffusion parameter extracted for characterization of a tissue being suspicious to a tumorous modification in magnetic resonance imaging is disclosed, wherein the phantom calibration body (110) is designed for being characterized during characterization of the tissue by the magnetic resonance imaging. Herein, the phantom calibration body (110) comprises a first compartment (112) having a first cross-section, the first compartment (112) being filled with a first solution comprising a calibration substance having a first concentration; and a second compartment (114) having a second cross-section, the second cross-section having at least two different partitions with differing diameters, wherein the second compartment (114) is filled with a second solution comprising the calibration substance having a second concentration, the second concentration differing from the first concentration. The present invention allows determining absolute quantitative parameters in an individualized fashion for each individual tissue independent from various times of recording, applied software algorithms for post-processing of the raw MRI data, MR devices, or MR vendors. The present invention, thus, allows using the absolute quantitative data extracted from the phantom calibration body (110) measured with every tissue for comparability of quantitative data, being a prerequisite for introducing quantitative diffusion weighted imaging (DWI) into clinical routine.
-
公开(公告)号：US11806395B2
公开(公告)日：2023-11-07
申请号：US17284528
申请日：2019-10-11
IPC分类号： A61K39/245 , C12N7/00 , A61K39/00
CPC分类号： A61K39/245 , C12N7/00 , A61K2039/5258 , A61K2039/572 , C12N2710/16023 , C12N2710/16034 , C12N2710/16071
摘要： The present invention relates to a preparation comprising Epstein-Barr virus-like particles (EB-VLPs), said EB-VLPs being essentially free of Epstein Barr virus (EBV) DNA, wherein said EB-VLPs comprise a vaccination polypeptide comprising at least one peptide of an EBV tegument polypeptide and at least one immunogenic peptide; and to polynucleotides, host cells, and methods related thereto.
-
公开(公告)号：US11806361B2
公开(公告)日：2023-11-07
申请号：US17218682
申请日：2021-03-31
发明人： Mathias Heikenwälder , Lars Zender , Achim Weber
IPC分类号： C07H21/02 , C07H21/04 , A61K31/7105 , A61P1/16 , A61K9/00 , A61K31/192 , A61K31/405 , A61K31/616 , C12N15/113 , A61K31/713 , A61K31/00
CPC分类号： A61K31/7105 , A61K9/0014 , A61K9/0019 , A61K9/0053 , A61K31/00 , A61K31/192 , A61K31/405 , A61K31/616 , A61K31/713 , A61P1/16 , C12N15/113 , C12N2310/11 , C12N2310/20
摘要： The present invention provides novel compounds that target thrombocyte activity or aggregation capacity through cellular components for the treatment of diseases associated with Non-Alcoholic Fatty Liver Disease (NAFLD). The invention provides these compounds for treating non-alcoholic steatohepatitis (NASH), a progressed stage of NAFL (non-alcoholic fatty liver), in order to avoid the development of liver cirrhosis and Hepatocellular Carcinoma (HCC). Further provided are pharmaceutical compositions, comprising the compounds of the invention, and methods for screening new NASH therapeuticals.
-
公开(公告)号：US11795164B2
公开(公告)日：2023-10-24
申请号：US17819602
申请日：2022-08-12
发明人： Ilona Gutcher , Norbert Schmees , Lars Röse , Benjamin Bader , Christina Kober , Rafael Carretero , Detlef Stöckigt , Horst Irlbacher , Michael Platten
IPC分类号： C07D417/04 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/04 , A61P35/00
CPC分类号： C07D417/04 , A61P35/00 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/04
摘要： The present invention covers 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamide compounds of general formula (1):
in which X, R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.-
公开(公告)号：US20230293690A1
公开(公告)日：2023-09-21
申请号：US18017636
申请日：2021-07-21
发明人： Richard Harbottle , Matthias Bozza
CPC分类号： A61K39/4632 , A61K39/4631 , A61K48/0066 , C12N15/85 , C12N2800/107
摘要： The instant invention relates to a therapeutic cell comprising an episomal polynucleotide comprising a promoter and an expressible sequence, wherein said episomal polynucleotide further comprises an S/MAR element upstream of said promoter. The present invention further relates to expression constructs, polynucleotides, animal host cells, expression constructs, vectors, and/or polynucleotides comprising a cargo sequence related thereto.
-
-
-
-
-
-
-
-
-
搜索结果
534 条记录 (耗时 0.033 秒)
